Kornimate/medical-research-clean huggingface dataset:
comorbidities and complications associated with covid-19 infection

Conditions: Covid19

Summary: to evaluate the spectrum of comorbidities and complications and its impact on the clinical outcome in hospitalized patients with coronavirus disease 2019 (covid-19).

severe acute respiratory syndrome (sars) coronavirus 2 (sars-cov-2) is a coronavirus with human infection designated as covid-19 by the world health organization. bats and birds serve as the typical coronavirus hosts, with zoonotic spread and a long-documented history of animal-animal-human transmission. since november 2019, the rapid outbreak of coronavirus disease 2019 (covid-19), which arose from severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection, has recently become a public health emergency of international concern. covid-19 has contributed to an enormous adverse impact globally. as of 10 march 2020 there have been 113702 laboratory confirmed cases and 4012 deaths globally. according to the latest reports, the clinical manifestations of covid-19 are heterogeneous. on admission, 20-51% of patients were reported as having at least one comorbidity, with diabetes (10-20%), hypertension (10-15%) and other cardiovascular and cerebrovascular diseases (7-40%) being most common. previous studies have demonstrated that the presence of any comorbidity has been associated with a 3.4-fold increased risk of developing acute respiratory distress syndrome in patients with h7n9 infection. as with influenza, sars-cov and middle east respiratory syndrome coronavirus (mers-cov), covid-19 is more readily predisposed to respiratory failure and death in susceptible patients. although it is well documented that covid-19 is primarily manifested as a respiratory tract infection, emerging data indicate that it should be regarded as a systemic disease involving multiple systems, including cardiovascular, respiratory, gastrointestinal, neurological, hematopoietic and immune system. mortality rates of covid-19 are lower than sars and middle east respiratory syndrome (mers); however, covid-19 is more lethal than seasonal flu. older people and those with comorbidities are at increased risk of death from covid-19, but younger people without major underlying diseases may also present with potentially lethal complications such as fulminant myocarditis and disseminated intravascular coagulopathy (dic).

Eligibility criteria:
inclusion criteria: patients presented by respiratory symptom and admitted to assuit university hospitals in wards and intensive care units due to covid-19 according to who and egyptian ministry of health and population (moh) definitions with positive pcr result. exclusion criteria: * negative pcr result for suspicious cases of covid-19, * patients refusing to participate in the study.
decitabine versus conventional chemotherapy for maintenance therapy of acute myeloid leukemia with t(8;21)

Conditions: Acute Myeloid Leukemia

Summary: acute myeloid leukemia (aml) is the most common hematological malignancies in adult patients with leukemia, and t(8;21) aml accounts for a substantial proportion of aml. aml patients with t(8;21) possess a favorable outcome and 3 - 4 course high dose cytarabine (3 g/m2) is the standard consolidation therapy for these patients with a 5-year overall survival approximately 60%. in china, intermediate dose cytarabine (1 - 2 g/m2) is used for consolidation therapy due to toxicities. after 3 - 4 course cytarabine consolidation, maintenance therapy is performed with conventional chemotherapy with a 5-year overall survival approximately 60% as well. however, continuous chemotherapy may cause toxicities and inhibit patients' immune response. exploring new drug for maintenance therapy is urgently needed. decitabine has a potent ability to inhibit proliferation and induce apoptosis of aml1-eto positive leukemia cell line. furthermore, the immunomodulatory effect of decitabine was also reported by several studies. in this study, the investigators plan to carry out a prospective, multicenter, randomized, controlled trail to compare decitabine versus conventional chemotherapy for maintenance therapy of patients with aml with t(8;21). results of this trial may optimize the treatment for aml patients with t(8;21) in the setting of intermediate dose cytarabine consolidation.


Eligibility criteria:
inclusion criteria: 1. patients are adults age ≥18 and ≤60 years 2. patients are diagnosed as aml with t(8;21) 3. continuous complete remission after induction and consolidation therapy with 3 - 4 course high dose cytarabine (2 g/m\^2) 4. patients whose aspartate transaminase (ast)/alanine transaminase (alt) are ≤ 2.5 times higher than the normal upper limit, total bilirubin ≤ 3.0 mg/dl, and serum creatinine ≤ 2.0 mg/dl. 5. subjects that signed the informed consent, which indicated they understood the purpose, the procedure and potential benefits of the trial and were willing to participate in the trial. exclusion criteria: 1. pregnant or lactating women. 2. ecog performance status score \> 2. 3. patients are candidates for hematopoietic stem cell transplantation. 4. patients with a history of use of azacitidine or decitabine. 5. patients with mental or other disorders that cannot completely cooperate with the treatment or follow up. 6. subjects that were allergic to decitabine vehicle. 7. patients receive immunotherapy. 8. patients also have other organ malignant tumor. 9. participating in other clinical research in the same period. 10. the researchers estimate that patients cannot enter the clinical trial.
reliability and validity of ultrasound for the assessment of soft tissue properties after breast cancer treatment

Conditions: Breast Neoplasms

Summary: after 1 year, more than 50% experience upper limb (ul) complaints after treatment for breast cancer. these complaints are disabling and cause limitations in daily life and this leads to a decrease in the patient's quality of life. the cause of these ul complaints is complex and multifactorial. due to breast cancer treatment, the structural (tissue composition and volume) and mechanical (tissue stiffness) properties of the soft tissue may change. these changes can occur in the muscle, skin and surrounding fascia and especially in the soft tissue around the breast and axilla where that treatment is localised. ultrasound with specific 'add-on' techniques can objectively assess these features and provide a picture of their role in ul function after breast cancer. the first aim in this study is to investigate the reliability and validity of conventional 2d ultrasound for 1) soft tissue composition and 2) soft tissue thickness at the level of the breast and upper limb. the reliability and validity of shear wave elastography, a specific complement to conventional 2d ultrasound, to assess tissue stiffness will also be examined.


Eligibility criteria:
1. breast cancer patients without upper limb dysfunctions (n=30) inclusion criteria * patients with unilateral primary breast cancer * surgery including, either: mastectomy with axillary lymph node dissection or sentinel lymph node biopsy or breast conserving surgery with axillary lymph node dissection or sentinel lymph node biopsy * at least 3 months after surgery or radiotherapy in order to take into account wound healing * comprehensive of the dutch language * quickdash score \<15/100 exclusion criteria: * bilateral surgery, widespread distance metastases, previous breast surgery * diagnosis of neurological or rheumatological condition * upper limb dysfunctions caused by other reasons 2. breast cancer patients with upper limb dysfunctions (n=30) inclusion criteria * patients with unilateral primary breast cancer * surgery including, either: mastectomy with axillary lymph node dissection or sentinel lymph node biopsy or breast conserving surgery with axillary lymph node dissection or sentinel lymph node biopsy * at least 3 months after surgery or radiotherapy in order to take into account wound healing * comprehensive of the dutch language * quickdash score \>15/100 exclusion criteria: * bilateral surgery, widespread distance metastases, previous breast surgery * diagnosis of neurological or rheumatological condition * upper limb dysfunctions caused by other reasons 3. healthy volunteers (n=30) inclusion criteria: * healthy women (quickdash \<15) age-matched with a breast cancer patient from the main study * comprehensive of the dutch language exclusion criteria: * upper limb dysfunctions * diagnosis of neurological or rheumatological condition, diabetes

Keywords: ultrasound upper limb dysfunctions
hepatitis b virus hbeag-negative genotype d patients and hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma; Hepatitis B

Summary: to evaluate the impact of liver fibrosis and other variables \[e.g., age, sex, virological response (vr), and previous resistance to nucleoside/nucleotide analogue (nuc) therapy\] on hepatocellular carcinoma incidence in an italian population of genotype d hbeag-negative chb patients treated with long-term nuc therapy.

hepatocellular carcinoma (hcc) usually develops in patients with chronic liver disease, particularly patients with liver cirrhosis. chronic hepatitis b (chb) is one of the most frequent underlying causes of hcc. several studies have demonstrated that variations in the hepatitis b virus (hbv) genotype have different effects on hcc. hbv genotypes c and d had lower responses to interferon-based therapy and higher frequencies of basal core promoter mutations than genotypes a and b.for this reason, hbv genotypes c and d seem to lead to more severe liver disease, including cirrhosis, compared with the other hbv genotypes. because liver cirrhosis is one of the strongest hcc risk factors in chb patients, antiviral therapy may prevent the development of liver complications such as hcc. the aim of this study is to evaluate the impact of liver fibrosis and other variables, such as age, sex, virological response (vr), and resistance to nucleoside/nucleotide analogue (nuc) therapy, in a population of genotype d hbeag-negative chb patients treated with long-term nuc therapy.

Eligibility criteria:
inclusion criteria: * only chronic hepatitis b or compensated cirrhosis hbeag-negative genotype d patients were included in this study.the patients were included in this study if they were ≥18 years old and had received treatment with nucleoside/nucleotide for a period of at least 18 months. exclusion criteria: * patients with hepatocellular carcinoma diagnosed before or during the first 18 months of nucleoside/nucleotide therapy, as well as patients coinfected with hepatitis d, hepatitis c, or hiv, were excluded. patients with decompensated cirrhosis were excluded because of the low number of cases observed.

Keywords: hepatocellular carcinoma hepatitis b
study to evaluate the immunogenicity and safety of 2 formulations of glaxosmithkline (gsk) biologicals' gsk1247446a low dose influenza vaccine candidate

Conditions: Influenza

Summary: the purpose of this study is to evaluate the immunogenicity and the safety of candidate vaccines compared to fluarix™ administered intramuscularly in subjects aged 18-59 years


Eligibility criteria:
inclusion criteria: * a male or female aged 18-59 years at the time of the first vaccination. * free of obvious health problems exclusion criteria: * use of non-registered products * administration of immune-modifying drugs. * administration of vaccine 30 days before enrolment in study. * immunosuppressive or immunodeficient condition. * hypersensitivity to a previous dose of influenza vaccine * previous vaccination against influenza in 2006 * acute or chronic clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality. * history of confirmed influenza infection within the last 12 months. * acute disease at the time of enrolment/vaccination. * history of allergy or reactions likely to be exacerbated by any component of the vaccine

Keywords: influenza vaccine prophylaxis influenza vaccine
efficacy, safety and tolerability of agomelatine in the treatment of major depressive disorder

Conditions: Major Depressive Disorder (MDD)

Summary: this study will assess efficacy, safety and tolerability of agomelatine (ago178) 25 mg and 50 mg in patients with major depressive disorder (mdd). this study includes an 8-week double-blind phase and a 52-week open-label phase.


Eligibility criteria:
inclusion criteria: * diagnosis of major depressive disorder, single or recurrent episode, according to dsm-iv criteria * ham-d17 total score \> or = 22 at screening and baseline * cgi-severity score \> or = 4 at screening and baseline * only patients who complete the core protocol are eligible to participate in the open-label extension phase exclusion criteria: * history of bipolar disorder (i or ii), schizophrenia, schizoaffective disorder, eating disorder, or obsessive compulsive disorder * any current axis i disorder other than major depressive disorder which is the focus of treatment * substance or alcohol abuse in the last 30 days, dependence in the last 6 months * concomitant psychotropic medication, including herbal preparations and melatonin * psychotherapy of any type * female patients of childbearing potential who are not using effective contraception other protocol-defined inclusion/exclusion criteria may apply

Keywords: agomelatine, major depressive disorder, mdd, depression
carbetocin at elective cesarean delivery

Conditions: Postpartum Hemorrhage

Summary: post-partum hemorrhage (pph) is a major cause of maternal death worldwide. oxytocin is the most commonly uterotonic drug used to prevent and treat pph in north america, however, there are some limitations to its use. oxytocin has a very short duration of action, which requires a continuous infusion to achieve sustained uterotonic activity. the society of obstetricians and gynecologists of canada (sogc) has recently recommended a single 100mcg dose of carbetocin at elective cesarean delivery to promote uterine contraction and prevent post partum hemorrhage (pph), in lieu of the more traditional oxytocin regimens. carbetocin lasts 4 to 7 times longer than oxytocin, with a similar side effect profile and apparent greater efficacy rate. however, a dose response to determine the minimum effective dose of carbetocin has not yet been published. we hypothesize that a dose-response study will establish the minimum dose of carbetocin required to produce appropriate contractility in 95% of the women (ed95) undergoing elective cesarean delivery.

the society of obstetricians and gynecologists of canada (sogc)recently recommended a 100mcg intravenous bolus dose of carbetocin following cesarean delivery. however, a dose response study to determine the minimum effective dose of carbetocin has not yet been published. studies thus far show that carbetocin may be just as effective as oxytocin in promoting uterine contraction, with a similar side effects profile. in addition, patients receiving carbetocin may experience less blood loss, and require less additional uterotonics when compared with oxytocin. the results of this study will define the minimum required dose of carbetocin for uterine contraction, thus minimizing unnecessary side effects, improving quality and safety of patient care. it may also contribute in establishing carbetocin as a substitute to oxytocin for elective cesarean section at our institution as well as others.

Eligibility criteria:
inclusion criteria: * all patients planned for elective cesarean delivery under spinal anesthesia; * all patients who gave written informed consent to participate in this study. exclusion criteria: * all patients who refuse to give written informed consent. * all patients who claim allergy or hypersensitivity to carbetocin or oxytocin. * all patients with conditions that predispose to uterine atony and postpartum hemorrhage such as placenta previa, multiple gestation, preeclampsia, eclampsia, macrosomia, polyhydramnios, uterine fibroids, previous history of uterine atony and postpartum bleeding, or bleeding diathesis. * all patients with hepatic, renal, and vascular disease, * all patients requiring general anesthesia prior to the administration of the study drug.

Keywords: pregnancy postpartum hemorrhage cesarean delivery carbetocin
posaconazole treatment of invasive fungal infection (ifi) (p05551)

Conditions: Fungal Infection

Summary: the purpose of this multicenter, open label study, is to evaluate the safety and efficacy of a 12-week treatment with posaconazole oral suspension in participants with ifi


Eligibility criteria:
inclusion criteria: * participants must be 18-70 years male or female * identified or clinically diagnosed ifi participants or high risk population who are resistant to, or recurrent from, or intolerable to, or may suffer toxic reaction from standard antifungal treatment. * sign informed consent form exclusion criteria: * female participants who are pregnant or are nursing. * participants with known or suspected hypersensitivity or idiosyncratic reaction to azole agents or amphotericin b * participants with progressive nervous system diseases( excluding those ifi caused) * participants who take the following drugs known with interference with azole antifungal preparations * terfenadine, cisapride, and ebastine within 24 hours before entry * astemizole at entry or within 10 days before entry * cimetidine, rifampin, carbamazepine, phenytoin, rifabutin, barbiturates, isoniazid atharanthine and anthracyclines within 24 hours before entry * the drugs listed above are prohibited during the investigation * serious organ diseases except hematological disorder such as cardiac or neurologic disorders or impairment expected to be unstable or progressive during the course of this study (eg, seizures or demyelinating syndromes, acute myocardial infarction within 3 months of study entry, myocardial ischemia, congestive heart failure, atrial fibrillation with ventricular rate \<60/min, or history of torsades de pointes, symptomatic ventricular or sustained arrhythmias), unstable electrolyte abnormalities. * participants having an ecg with a prolonged qtc interval: qtc greater than 450 msec for men and greater than 470 msec for women. * expected to take during investigation or is taking systemic antifungal treatment * participants with severe renal insufficiency (estimated creatinine clearance less than 50 ml/minute or likely to require dialysis during the study), alt,ast akp or total bilirubin are \>2×uln. * participants expected to survive no more than 72hrs * participants receiving artificial aeration and will not withdraw within 24hrs * participants who have used any investigational drugs or biologic agents or anticipated other clinical trials within 30 days of study entry. * prior enrollment in this study. * history of alcohol and/or drug abuse. * participants cannot be compliant in investigator's opinion.

Keywords: refractory or first line medication intolerable invasive fungal infection
corona (covid-19) follow up study: epidemiology, pathophysiology, prediction, and communication

Conditions: COVID-19; Long COVID; Post COVID-19 Condition

Summary: the corfu study, funded by zonmw, is a prospective, multiple, cohort study with a maximum follow-up of 24 months after covid-19. dutch covid-19 patients from 7 existing prospective cohorts, aiming and designed to conduct covid-19 research, will be included in this study. the corfu study has 5 aims, divided into 4 work packages (wps): 1. to describe the nature, severity, pattern and duration of long covid complaints up to a maximum of two years after infection and its relationship with quality of life (wp1); 2. to describe the rehabilitation and corresponding activities for the treatment and improvement of complaints and quality of life (wp1); 3. to describe the pathophysiological processes that cause long covid complaints, and the role of vulnerability/resilience factors (wp2); 4. to develop a prediction model for the persistence of complaints, with distinction between patients with and without pre-existing morbidity (wp3); 5. to develop a patient platform prototype in which patients can digitally consult their answers and compare their answers with reference populations (wp4, in collaboration with the euroqol foundation). the 7 cohorts participating in the corfu study are: popcorn, covas, elvis, maastriccht, dc\&tc, capacity-covid, and adelante cohort. (clinical) baseline and follow-up data has been collected in these cohorts and will be used/aggregated to investigate corfu study aims. in addition, questionnaires will be send to the (former) patients of the existing cohorts and patients will be asked about several domains such as persisting complaints and quality of life, at several moments, depending on when the patients have experienced covid-19. within this study a patient platform prototype will be developed, together with the euroqol foundation, to be able to inform patients about the individual situation and course of disease.


Eligibility criteria:
all 7 existing cohorts have specific inclusion and exclusion criteria. for the corfu study, in general, the criteria are: patients with proven or suspected covid-19: * confirmed (or suspected) covid-19 - both home-isolated patients and patients who were admitted to the hospital ward and/or icu; * included in one of the seven cohorts from march 2020 onwards; * aged 18 years or older; * mastering the dutch language sufficiently to answer the questionnaires; * informed consent. controls who did not experience covid-19: * aged 18 years or older; * mastering the dutch language sufficiently to answer the questionnaires; * informed consent. there were no exclusion criteria.

Keywords: epidemiology pathophysiology prediction model patient platform
umbilical cord mesenchymal stem cells injection for ocular corneal burn

Conditions: Ocular Corneal Burn

Summary: ocular chemical burn is one of the causes of vision loss in china, and there are no satisfactory treatment. human umbilical cord mesenchymal stem cells(uc-mscs) have the biological characteristics of self-renewal, immune regulation, multidirectional differentiation and tissue repair. our preliminary research showed that in corneal alkali injury rabbits, the uc-mscs can accelerated the cornea repair, inhibited angiogenesis. the aim of this study is to access the efficacy and safety of uc-mscs in the treatment of corneal burn in human.


Eligibility criteria:
inclusion criteria: * must be ocular burns including chemically burned or the thermally burned; * the subjects are willing to accept this research, and promise to coordinate with the researchers during the follow up period; * the subjects should abide by the laws and rules of the study. exclusion criteria: * the visual acuity is blind in any of the eye; * have corneal perforation or have the corneal perforation tendency; * have been accepted surgery on eyeball after trauma; * iop\>=25 mmhg even after antiglaucoma; * have the history of other corneal disease or surgery; * have the history of radiotherapy or surgery in the eyeball; * associated with corneal ulcer or endoophthalmitis; * uncontrolled hypertension(\>=150/95 mmhg); * abnormal liver and renal function; * the pregnant women.